Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial

Authors: Blagden, Sarah P ^*, Cook, Adrian D, Poole, Christopher, Howells, Lesley, McNeish, Ian A, Dean, Andrew, Kim, Jae-Weon, O'Donnell, Dearbhaile M, Hook, Jane, James, Elizabeth C, White, Ian R, Perren, Timothy, Lord, Rosemary, Dark, Graham, Earl, Helena M, Hall, Marcia, Kaplan, Richard, Ledermann, Jonathan A, Clamp, Andrew R

Source: In The Lancet Oncology July 2020 21(7):969-977

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

Authors: Clamp, Andrew R, James, Elizabeth C ^*, McNeish, Iain A, Dean, Andrew, Kim, Jae-Weon, O'Donnell, Dearbhaile M, Hook, Jane, Coyle, Christopher, Blagden, Sarah, Brenton, James D, Naik, Raj, Perren, Tim, Sundar, Sudha, Cook, Adrian D, Gopalakrishnan, Gosala S, Gabra, Hani, Lord, Rosemary, Dark, Graham, Earl, Helena M, Hall, Marcia, Banerjee, Susana, Glasspool, Rosalind M, Jones, Rachel, Williams, Sarah, Swart, Ann Marie, Stenning, Sally, Parmar, Mahesh, Kaplan, Richard, Ledermann, Jonathan A

Source: In The Lancet 7-13 December 2019 394(10214):2084-2095

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Authors: Agarwal, Roshan, Algurafi, Hafiz, Allerton, Rozenn, Archer, Caroline, Armstrong, Anne, Bale, Catherine, Barraclough, Lisa, Barthakur, Urmila, Bedi, Carolyn, Benstead, Kim, Bloomfield, David, Bowen, Rebecca, Bradley, Chris, Brown, Jane, Butt, Mohammad, Churn, Mark, Cleator, Susan, Cliff, Joanne, Crellin, Perric, Daly, Margaret, De Silva-Minor, Shiroma, Dhadda, Amandeep, Din, Omar, Down, Sue, Earl, Helena, Eaton, David, Eichholz, Andrew, Epurescu, Daniel, Goh, Chee, Goodman, Andrew, Grieve, Robert, Hadaki, Maher, Harper-Wynne, Catherine, Harries, Mark, Hayward, Larry, Humphreys, Alison, Innes, Helen, Jafri, Mariam, Jegannathen, Apurna, Kelleher, Muireann, Kristeleit, Hartmut, Lee, Daniela, Lupton, Susan, MacGregor, Carol, Malik, Zafar, Mansi, Janine, Marshall, Jennifer, McAdam, Karen, McGolick, Trevor, Mehra, Rakesh, Miles, David, Mithal, Natasha, Moss, Charlotte, Moss, Aian, Mukesh, Mukesh, Neal, Anthony, Nelmes, Daniel, Neville-Webbe, Helen, Newby, Jacqueline, O'Reilly, Susan, Ostler, Peter, Persic, Mojca, Pettit, Laura, Raj, Sanjay, Raja, Fharat, Rea, Daniel, Reed, Catherine, Rigg, Anne, Roe, Helen, Shah, Nihal, Simmonds, Peter, Sims, Eliot, Smith, Sarah, Storey, Nicola, Taylor, Wendy, Thanvi, Narottam, Tipples, Karen, Vaidya, Jayant, Varughese, Mohini, Vinayan, Anup, Walji, Nawaz, Waters, Simon, Woodings, Pamela, Wright, Kathryn, Yahya, Sundus, Earl, Helena M, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Howe, Donna, Raynes, Kerry, Higgins, Helen B, Wilcox, Maggie, Plummer, Chris, Gounaris, Ioannis, Mahler–Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Abraham, Jean E, Caldas, Carlos, Hall, Peter S, McCabe, Christopher, Hulme, Claire, Wardley, Andrew M, Cameron, David A, Dunn, Janet A

Source: In The Lancet 29 June-5 July 2019 393(10191):2599-2612

Sodium MRI with 3D-cones as a measure of tumour cellularity in high grade serous ovarian cancer

Authors: Deen, Surrin S., Riemer, Frank, McLean, Mary A., Gill, Andrew B., Kaggie, Joshua D., Grist, James T., Crawford, Robin, Latimer, John, Baldwin, Peter, Earl, Helena M., Parkinson, Christine A., Smith, Sarah A., Hodgkin, Charlotte, Moore, Elizabeth, Jimenez-Linan, Mercedes, Brodie, Cara R., Addley, Helen C., Freeman, Susan J., Moyle, Penelope L., Sala, Evis, Graves, Martin J., Brenton, James D., Gallagher, Ferdia A.

Source: In European Journal of Radiology Open 2019 6:156-162

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Authors: Earl, Helena M, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel, Raj, Sanjay, Woodings, Pamela, Harries, Mark, Howe, Donna, Raynes, Kerry, Higgins, Helen B, Wilcox, Maggie, Plummer, Chris, Mansi, Janine, Gounaris, Ioannis, Mahler–Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Abraham, Jean E, Caldas, Carlos, Hall, Peter S, McCabe, Christopher, Hulme, Claire, Miles, David, Wardley, Andrew M, Cameron, David A, Dunn, Janet A

Source: Lancet. 393(10191):2599-2612

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100111569766.0x000001&indx=1&recIds=ETOCvdc_100111569766.0x000001

Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial

Authors: Earl, Helena M, Hiller, Louise, Howard, Helen C, Dunn, Janet A, Young, Jennie, Bowden, Sarah J, McDermaid, Michelle, Waterhouse, Anna K, Wilson, Gregory, Agrawal, Rajiv, O'Reilly, Susan, Bowman, Angela, Ritchie, Diana M, Goodman, Andrew, Hickish, Tamas, McAdam, Karen, Cameron, David, Dodwell, David, Rea, Daniel W, Caldas, Carlos, Provenzano, Elena, Abraham, Jean E, Canney, Peter, Crown, John P, Kennedy, M John, Coleman, Robert, Leonard, Robert C, Carmichael, James A, Wardley, Andrew M, Poole, Christopher J

Source: In The Lancet Oncology June 2017 18(6):755-769

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

Authors: Abraham, Jean E., Pinilla, Karen, Dayimu, Alimu, Grybowicz, Louise, Demiris, Nikolaos, Harvey, Caron, Drewett, Lynsey M., Lucey, Rebecca, Fulton, Alexander, Roberts, Anne N., Worley, Joanna R., Chhabra, Anita, Qian, Wendi, Vallier, Anne-Laure, Hardy, Richard M., Chan, Steve, Hickish, Tamas, Tripathi, Devashish, Venkitaraman, Ramachandran, Persic, Mojca, Aslam, Shahzeena, Glassman, Daniel, Raj, Sanjay, Borley, Annabel, Braybrooke, Jeremy P., Sutherland, Stephanie, Staples, Emma, Scott, Lucy C., Davies, Mark, Palmer, Cheryl A., Moody, Margaret, Churn, Mark J., Newby, Jacqueline C., Mukesh, Mukesh B., Chakrabarti, Amitabha, Roylance, Rebecca R., Schouten, Philip C., Levitt, Nicola C., McAdam, Karen, Armstrong, Anne C., Copson, Ellen R., McMurtry, Emma, Tischkowitz, Marc, Provenzano, Elena, Earl, Helena M.

Source: Nature; May 2024, Vol. 629 Issue: 8014 p1142-1148, 7p

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial

Authors: Earl, Helena M, Hiller, Louise, Dunn, Janet A, Blenkinsop, Clare, Grybowicz, Louise, Vallier, Anne-Laure, Abraham, Jean, Thomas, Jeremy, Provenzano, Elena, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Chan, Stephen, Ahmad, Rizvana, Hickish, Tamas, Houston, Stephen, Rea, Daniel, Bartlett, John, Caldas, Carlos, Cameron, David A, Hayward, Larry

Source: In The Lancet Oncology June 2015 16(6):656-666

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial

Authors: Earl, Helena M, Vallier, Anne-Laure, Hiller, Louise, Fenwick, Nicola, Young, Jennie, Iddawela, Mahesh, Abraham, Jean, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Houston, Stephen, Hickish, Tamas, Skene, Anthony, Chan, Stephen, Dean, Susan, Ritchie, Diana, Laing, Robert, Harries, Mark, Gallagher, Christopher, Wishart, Gordon, Dunn, Janet, Provenzano, Elena, Caldas, Carlos

Source: In Lancet Oncology February 2014 15(2):201-212

Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience: too toxic for relapse?

Authors: Gounaris, Ioannis, Iddawela, Mahesh, Parkinson, Christine, Pratt, Jennie, Hatcher, Helen, Basu, Bristi, Tan, Li Tee, Brenton, James D., Earl, Helena M.

Source: Anti-cancer drugs. 27(3):239-244

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100032612671.0x000001&indx=1&recIds=ETOCvdc_100032612671.0x000001

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis

Authors: Escala-Garcia, Maria, Abraham, Jean, Andrulis, Irene L., Anton-Culver, Hoda, Arndt, Volker, Ashworth, Alan, Auer, Paul L., Auvinen, Päivi, Beckmann, Matthias W., Beesley, Jonathan, Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Blomqvist, Carl, Blot, William, Bogdanova, Natalia V., Bojesen, Stig E., Bolla, Manjeet K., Børresen-Dale, Anne-Lise, Brauch, Hiltrud, Brenner, Hermann, Brucker, Sara Y., Burwinkel, Barbara, Caldas, Carlos, Canzian, Federico, Chang-Claude, Jenny, Chanock, Stephen J., Chin, Suet-Feung, Clarke, Christine L., Couch, Fergus J., Cox, Angela, Cross, Simon S., Czene, Kamila, Daly, Mary B., Dennis, Joe, Devilee, Peter, Dunn, Janet A., Dunning, Alison M., Dwek, Miriam, Earl, Helena M., Eccles, Diana M., Eliassen, A. Heather, Ellberg, Carolina, Evans, D. Gareth, Fasching, Peter A., Figueroa, Jonine, Flyger, Henrik, Gago-Dominguez, Manuela, Gapstur, Susan M., García-Closas, Montserrat, García-Sáenz, José A., Gaudet, Mia M., George, Angela, Giles, Graham G., Goldgar, David E., González-Neira, Anna, Grip, Mervi, Guénel, Pascal, Guo, Qi, Haiman, Christopher A., Håkansson, Niclas, Hamann, Ute, Harrington, Patricia A., Hiller, Louise, Hooning, Maartje J., Hopper, John L., Howell, Anthony, Huang, Chiun-Sheng, Huang, Guanmengqian, Hunter, David J., Jakubowska, Anna, John, Esther M., Kaaks, Rudolf, Kapoor, Pooja Middha, Keeman, Renske, Kitahara, Cari M., Koppert, Linetta B., Kraft, Peter, Kristensen, Vessela N., Lambrechts, Diether, Le Marchand, Loic, Lejbkowicz, Flavio, Lindblom, Annika, Lubiński, Jan, Mannermaa, Arto, Manoochehri, Mehdi, Manoukian, Siranoush, Margolin, Sara, Martinez, Maria Elena, Maurer, Tabea, Mavroudis, Dimitrios, Meindl, Alfons, Milne, Roger L., Mulligan, Anna Marie, Neuhausen, Susan L., Nevanlinna, Heli, Newman, William G., Olshan, Andrew F., Olson, Janet E., Olsson, Håkan, Orr, Nick, Peterlongo, Paolo, Petridis, Christos, Prentice, Ross L., Presneau, Nadege, Punie, Kevin, Ramachandran, Dhanya, Rennert, Gad, Romero, Atocha, Sachchithananthan, Mythily, Saloustros, Emmanouil, Sawyer, Elinor J., Schmutzler, Rita K., Schwentner, Lukas, Scott, Christopher, Simard, Jacques, Sohn, Christof, Southey, Melissa C., Swerdlow, Anthony J., Tamimi, Rulla M., Tapper, William J., Teixeira, Manuel R., Terry, Mary Beth, Thorne, Heather, Tollenaar, Rob A. E. M., Tomlinson, Ian, Troester, Melissa A., Truong, Thérèse, Turnbull, Clare, Vachon, Celine M., van der Kolk, Lizet E., Wang, Qin, Winqvist, Robert, Wolk, Alicja, Yang, Xiaohong R., Ziogas, Argyrios, Pharoah, Paul D. P., Hall, Per, Wessels, Lodewyk F. A., Chenevix-Trench, Georgia, Bader, Gary D., Dörk, Thilo, Easton, Douglas F., Canisius, Sander, Schmidt, Marjanka K.

Source: Nature communications. 11(1)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100131055114.0x000001&indx=1&recIds=ETOCvdc_100131055114.0x000001

The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge

Authors: Abraham, Jean E, Anderson, Benjamin O, André, Fabrice, Barrios, Carlos H, Bliss, Judith M, Boughey, Judy C, Cameron, David A, Cardoso, Fatima V, Carey, Lisa A, Chatterjee, Sanjoy, Coles, Charlotte E, Cuzick, Jack, Du Plooy, Dorothy, Francis, Prudence A, Gralow, Julie R, Jagsi, Reshma, Knaul, Felicia M, Ma, Fei, Mann, Ritse M, McIntosh, Stuart A, Mertz, Shirley A, Mutebi, Miriam, Olopade, Funmi, Phillips, Kelly-Anne, Poortmans, Philip M, Spanic, Tanja, Spence, Dingle, Stobart, Hilary, Symmans, Fraser WF, Villarreal-Garza, Cynthia, Yip, Cheng-Har, Bienz, Maya J, Drewett, Lynsey M, Fulton, Alex, Inbah Rajah, Dharrnesha, Kazmi, Farasat, Rubasingham, Jeffrey, Thompson, Mareike, Vargas, Valentina, Arreola, Hector, Badwe, Raj A, Calderon Anyosa, Renzo JC, Dave, Rajiv V, De-Graft Aikins, Ama, Earl, Helena M, Essue, Beverley M, Etzioni, Ruth B, Hawley, Sarah T, Jiang, Xiaoxiao, Mittra, Indraneel, Moreno, Patricia I, Nargund, Renu Sara, Noble, Cara, Smith, Robert A, Verhoeven, Didier, Wang, Jiani N, Watkins, David A, Zikmund-Fisher, Brian J, Coles, Charlotte Elizabeth, Cameron, David, Cardoso, Fatima, Horton, Richard, Knaul, Felicia Marie, Lee, Naomi

Source: In The Lancet 19-25 March 2022 399(10330):1101-1103

Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer

Authors: Deen, Surrin S., Priest, Andrew N., McLean, Mary A., Gill, Andrew B., Brodie, Cara, Crawford, Robin, Latimer, John, Baldwin, Peter, Earl, Helena M., Parkinson, Christine, Smith, Sarah, Hodgkin, Charlotte, Patterson, Ilse, Addley, Helen, Freeman, Susan, Moyle, Penny, Jimenez-Linan, Mercedes, Graves, Martin J., Sala, Evis, Brenton, James D., Gallagher, Ferdia A.

Source: Scientific reports. 9(1)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100131461400.0x000001&indx=1&recIds=ETOCvdc_100131461400.0x000001

Safe de-escalation of chemotherapy in HER2-positive early breast cancer

Authors: Earl, Helena M

Source: In The Lancet 27 April-3 May 2024 403(10437):1606-1607

Protective strategies to prevent trastuzumab-induced cardiotoxicity – Authors' reply

Authors: Earl, Helena M, Hiller, Louise, Plummer, Chris, Miles, David, Wardley, Andrew M, Cameron, David A, Dunn, Janet A

Source: Lancet. 395(10223):492-493

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100115810876.0x000001&indx=1&recIds=ETOCvdc_100115810876.0x000001

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results

Authors: Hiller, Louise, Dunn, Janet A., Loi, Shrushma, Vallier, Anne-Laure, Howe, Donna L., Cameron, David A., Miles, David, Wardley, Andrew M., Earl, Helena M.

Source: BMC cancer. 18(1)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100129444482.0x000001&indx=1&recIds=ETOCvdc_100129444482.0x000001

The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel

Authors: Ahmed, Ahmed Ashour, Mills, Anthony D., Ibrahim, Ashraf E.K., Temple, Jillian, Blenkiron, Cherie, Vias, Maria, Massie, Charlie E., Iyer, N. Gopalakrishna, McGeoch, Adam, Crawford, Robin, Nicke, Barbara, Downward, Julian, Swanton, Charles, Bell, Stephen D., Earl, Helena M., Laskey, Ronald A., Caldas, Carlos, Brenton, James D.

Source: In Cancer Cell 6 December 2007 12(6):514-527

Optimising patient recall of adverse events over prolonged time periods

Authors: Hiller Louise, Dunn Janet A, Higgins Helen B, Ogburn-Storey Emma, Loi Shrushma, Vallier Anne-Laure, Earl Helena M

Source: Trials, Vol 12, Iss Suppl 1, p A74 (2011)

Subject Terms: Medicine (General), R5-920

File Description: electronic resource

Relation: https://doaj.org/toc/1745-6215

Access URL: https://doaj.org/article/5b4630e43fa5494fb1c391bd54e492e9

Pharmacogenetics of cancer chemotherapy

Authors: Abraham, Jean, Earl, Helena M., Pharoah, Paul D., Caldas, Carlos

Source: In BBA - Reviews on Cancer 2006 1766(2):168-183

Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer.

Authors: Poole, Christopher J., Earl, Helena M., Hiller, Louise

Source: New England Journal of Medicine; November 2 2006, Vol. 355 Issue 18, p1851-1862, 12p